If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
184
results.
Updated on
22/10/2026 [11:17:00]
Results 50 to 75 of 184
Absstract of: AU2025239656A1
The present disclosure provides anti-tau antibodies, including compositions and methods of using such antibodies for treating Alzheimer's disease.
Absstract of: AU2025239644A1
Provided herein are medical uses of CD11a-enriched T regulatory cells for treating amyotrophic lateral sclerosis (ALS) or ameliorating a symptom of ALS. Such uses may include longitudinal analysis of biomarkers, such as inflammatory cytokines.
Absstract of: US20260297079A1
0000 The present invention relates to an aromatic heterocycle-fused cyclohexyl aminoalkyl piperidine derivative, a preparation method and use thereof. Specifically, the present invention provides a compound of general formula (I), a stereoisomer thereof, a tautomer thereof, or a pharmaceutically acceptable salt thereof, and a preparation method therefor, use thereof for activating the activities of a 5-HT<1A >receptor and dopamine D<2 >and D<3 >receptors, and use thereof in the preparation of a medicament for Parkinson's disease.
0000
Absstract of: US20260297217A1
0000 Provided herein are methods of treating diseases and disorders related to TDP-43 aggregation (e.g., ALS) with an antibody that specifically binds to OxPC or a polynucleotide encoding an antibody that specifically binds to OxPC.
Absstract of: US20260297085A1
This disclosure relates to compounds of Formula (I-1) or (I-2): The compounds of the present disclosure are capable of inhibiting the activity of tyrosine kinase 2 (TYK2) and are useful for the treatment of diseases or disorders, such as e.g. inflammation, autoimmune disease, neuroinflammation, arthritis, rheumatoid arthritis, spondyloarthropathies, systemic lupus erythematous, lupus nephritis, arthritis, osteoarthritis, gouty arthritis, pain, fever, pulmonary sarcoisosis, silicosis, cardiovascular disease, atherosclerosis, myocardial infarction, thrombosis, congestive heart failure and cardiac reperfusion injury, cardiomyopathy, stroke, ischaemia, reperfusion injury, brain edema, brain trauma, neurodegeneration, liver disease, inflammatory bowel disease, Crohn's disease, ulcerative colitis, nephritis, retinitis, retinopathy, macular degeneration, glaucoma, diabetes (type 1 and type 2), diabetic neuropathy, viral and bacterial infection, myalgia, endotoxic shock, toxic shock syndrome, autoimmune disease, osteoporosis, multiple sclerosis, endometriosis, menstrual cramps, vaginitis, candidiasis, cancer, fibrosis, obesity, muscular dystrophy, polymyositis, dermatomyositis, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, vitiligo, alopecia, Alzheimer's disease, skin flushing, eczema, psoriasis, atopic dermatitis and sunburn. The disclosure further provides methods of preparing the compounds.
Absstract of: US20260294922A1
The present disclosure relates, in part, to compounds of Formula (I) and (II), which selectively inhibit JUN N-Terminal Kinases (JNK1, JNK2, and/or JNK3; also known as MAPK8, MAPK9, and/or MAPK10), pharmaceutical compositions thereof, and methods of using the same for the treatment, prevention, and/or amelioration of one or more diseases and/or disorders in a subject. In certain embodiments, the inflammatory disease or disorder is endometriosis, arthritis, pulmonary fibrosis, cancer, type 1 and/or 2 diabetes, Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis. In certain embodiments, the methods described herein further comprise detecting the disease and/or disorder in the subject with a suitable diagnostic method.
Absstract of: US20260294875A1
An agent for treating or preventing amyotrophic lateral sclerosis, wherein an active component of the agent essentially consists of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The active component may consist of at least one selected from the group consisting of cycloserine, terizidone, and salts thereof. The cycloserine may be D-cycloserine. The cycloserine may be L-cycloserine.
Absstract of: US20260297571A1
0000 The present disclosure provides compositions and methods for treating ALS and/or FTD and for reducing neuroinflammation and neurodegeneration, e.g., as caused by dipeptide repeat (DPR) toxicity. Particularly, the disclosure provides methods for improving neuron survival, decreasing neuroinflammation and treating ALS and/or FTD using PTPσ inhibitors.
Absstract of: US20260295017A1
This disclosure belongs to the technical field of biomedicine, and discloses use of a mimetic peptide containing a fibrinogen RGD motif in preparation of medications for preventing and/or treating Parkinson's disease. A sequence of the mimetic peptide containing the fibrinogen RGD motif of this disclosure is: Gly-Arg-Gly-Asp-Ser-Pro-Leu-Ala-Pro-Ser-Cys. The applicant of this disclosure has found through research that there is abnormal accumulation of FG in substantia nigra pars compacta of PD mice, and that excessively accumulated FG in the brain may promote abnormal aggregation of α-syn in dopaminergic neurons under mediation of αvβ3 integrin receptor. The mimetic peptide provided by this disclosure can effectively inhibit the abnormal aggregation of α-syn in the dopaminergic neurons and death of the dopaminergic neurons caused by the abnormally accumulated FG in the brain, improve a motion ability of MPTP-modeled PD mice, and provide a new target and idea for PD treatment.
Absstract of: AU2025224578A1
A self-inactivating CRISPR/Cas9 delivery system utilizing a dual vector system may be provided. A first viral vector includes an expression unit for expression of a Cas9 nuclease and a nucleotide sequence encoding an sgRNA targeting a specific genomic locus. The second viral vector includes a nucleotide sequence encoding an sgRNA targeting expression of the Cas9 nuclease by the expression unit. The self-inactivating CRISPR/Cas9 dual vector delivery system can be used for treating a genetic gene-associated disease/disorder and/or a sporadic gene-associated disease/disorder. In embodiments, the disease and/or disorder may be a neurological disease and/or disorder. In embodiments, neurological disease and/or disorder may be Huntington's disease. Methods of treatment, medicaments, and pharmaceutical compositions may be provided.
Absstract of: WO2026199817A1
The present application provides a method for preparing a humanized Aβ1-40 antibody and use thereof. Specifically, the antibody of the present application combines a murine antibody variable region and a human antibody framework region; on the basis of specifically binding to an Aβ peptide segment, the antibody reduces immunogenicity due to its humanized framework region. The antibody has the advantages of high affinity, high specificity, low immunogenicity, and scalability for large-scale production. The antibody of the present application can be used for detecting an Aβ1-40 antigen, eliminating Aβ deposits, or treating related diseases thereof, such as Alzheimer's disease.
Absstract of: WO2026202512A1
The invention relates to antibodies, and specifically to anti-amyloid-beta (Aβ) antibodies. The invention extends to compositions comprising the antibodies, including pharmaceutical compositions and kits. The invention also extends to methods of making and using the antibodies, for example in therapy and diagnosis of Aβ-mediated 5 conditions, such as Alzheimer's disease.
Absstract of: WO2026202374A1
The present invention relates to anti-Tau biparatopic bispecific antibodies (referred as Tau biparatopic κλ-bodies) or fragments thereof, or a mixture, to be used for the prevention, and treatment of tauopathies including Alzheimer's disease. The antibodies could also be used for diagnosis purposes before or after symptoms occur. Lastly, it could be used to monitor the treatment effect.
Absstract of: WO2026199818A1
The present application provides a method for preparing a humanized Aβ1-42 antibody and use thereof. Specifically, the antibody of the present application combines a murine antibody variable region and a human antibody framework region; on the basis of specifically binding to an Aβ peptide segment, the antibody reduces immunogenicity due to its humanized framework region. The antibody has the advantages of high affinity, high specificity, low immunogenicity, and scalability for large-scale production. The antibody of the present application can be used for detecting an Aβ1-42 antigen, eliminating Aβ deposits, or treating related diseases thereof, such as Alzheimer's disease.
Absstract of: EP4813991A1
Provided are a novel compound, a use thereof for inhibiting the activity of CDK12 and/or CDK13 and degrading cyclin K, a pharmaceutical composition comprising the same, and a use thereof for the treatment of diseases associated with CDK12 and/or CDK13 and/or cyclin K, such as cancer. According to the present invention, the compounds exhibit excellent inhibitory activity and selectivity against CDK12 and/or CDK13, and induce degradation of cyclin K, and thus can be useful for the treatment of cancers such as breast cancer or gastric cancer.
Absstract of: EP4813985A1
Provided are a compound represented by formula I, a stereoisomer, a deuterated substance, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition containing same, as well as the use thereof as a BRAF regulator in the preparation of a drug for treating related diseases. Each group in formula (I) is as defined in the description.
Absstract of: KR20260143072A
본 발명은 화학식 1로 표시되는 화합물을 포함하는 근위축성 측삭경화증(ALS)을 예방, 치료, 또는 개선하는 데 사용하기 위한 조성물 및 이의 용도에 관한 것이다. 본 발명의 조성물은 근위축성 측삭경화증(ALS) 및/또는 관련 증상을 예방, 치료 또는 호전시키는 데 탁월한 효과를 나타낼 수 있다.
Absstract of: EP4813390A2
Provided herein are compounds according to Formula (I)or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
Absstract of: US20260283995A1
0000 What is provided is a method for treating olfactory disorders, multiple sclerosis, metachromatic leukodystrophy, paralysis, sensory disorders, cognitive dysfunction, Alzheimer's disease, amyotrophic lateral sclerosis, schizophrenia, bipolar disorders, stress, fatigue or anxiety disorders, including administering an effective amount of linalyl acetate, α-terpineol or 1,8-cineole to a subject in need thereof.
Absstract of: WO2026193686A1
The present invention belongs to the technical field of biopharmaceutics, and specifically relates to a pharmaceutical composition for preventing and/or treating Alzheimer's disease. Provided in the present invention is an NPAFP protein-based pharmaceutical composition. The composition exhibits significant effects in anti-oxidation, improving mitochondrial quality, reducing the secretion of Aβ42, ameliorating the pathological state caused by Tau PFF, etc., thereby providing a new idea for the prevention and treatment of Alzheimer's disease.
Absstract of: US20260284023A1
Methods of use of CFTR corrector compounds, particularly lumacaftor and tezacaftor, to treat reduced cerebral perfusion associated with heart failure, sudden sensoneurinal hearing loss, vascular dementia, arterial hypertension, ischemic stroke, hemorrhagic stroke, heart disease, diabetes and Alzheimer's disease by treatment with an amount sufficient to provide a proteostatic effect on cystic fibrosis transmembrane conductance regulator (CFTR) protein expression in cerebral artery smooth muscle cells and an increase in cerebrovascular perfusion in the patient.
Absstract of: DE102025111075A1
Die vorliegende Erfindung betrifft ein Verfahren zur Herstellung von dopaminergen neuronalen Organoiden (d-NOs) mit Nachweis der Dopaminfreisetzung in biologisch wirksamen Konzentrationen. Darüber hinaus umfassen d-NOs neben dopaminergen Neuronen auch funktionell miteinander verbundene GABAerge, glutamaterge und cholinerge Neuronen sowie Gliazellen, wodurch sie zu einem multizellulären Organoid mit einer für das Mittelhirn repräsentativen Zellzusammensetzung und Funktion werden. Daher zeigen die d-NOs der Erfindung eine komplexe Regulation dopaminerger Neuronen durch verwandte exzitatorische und inhibitorische Neuronen, was auf Kontrollmechanismen hindeutet, die beispielsweise eine Überproduktion und Freisetzung von Dopamin verhindern können. Die Erfindung bezieht sich auch auf die n-NOs als Implantat oder zur Verwendung bei der Behandlung der Parkinson-Krankheit. Darüber hinaus bezieht sich die Erfindung auf die Verwendung der d-NOs für Wirkstoffscreenings.
Absstract of: WO2026198526A1
The present disclosure provides compositions and methods for treating a subject afflicted with or at risk of developing a neurological condition, including a synucleinopathy such as Parkinson's disease, increasing mitochondrial function, reducing alpha-synuclein aggregation, and decreasing cellular oxidative stress. Aspects of the disclosure further relate to molybdenum diselenide nanomaterial compositions and combinatorial therapies for neuroprotection.
Absstract of: WO2026198539A1
The present disclosure provides products and methods for modulating brain lipid function and dysfunction in a subject. In some aspects the methods are useful for slowing the progression of or preventing the development of Alzheimer's Disease or for treating Alzheimer's disease. The disclosure provides the results of a genome-wide CRISPR screening to reveal regulators of oligodendrocyte lipid dysfunction.
Nº publicación: AU2025235730A1 24/09/2026
Applicant:
WASHINGTON UNIV
WASHINGTON UNIVERSITY
Absstract of: AU2025235730A1
The present disclosure is generally directed to tetracyclic analogs that modulate autophagy in a subject suffering from alpha-1 antitrypsin deficiency (ATD) and possibly other autophagy associated diseases or disorders, such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis.
BOPI
Electronic site
